EBS Stock Summary and Trading Ideas (Emergent Biosolutions | NYSE:EBS)

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent Biosolutions trades on the NYSE stock market under the symbol EBS.

As of December 12, 2025, EBS stock price declined to $11.41 with 534,981 million shares trading.

EBS has a beta of 2.19, meaning it tends to be more sensitive to market movements. EBS has a correlation of 0.18 to the broad based SPY ETF.

EBS has a market cap of $599.25 million. This is considered a Small Cap stock.

Last quarter Emergent Biosolutions reported $231 million in Revenue and $1.06 earnings per share. This beat revenue expectation by $33 million and exceeded earnings estimates by $1.09.

In the last 3 years, EBS traded as high as $16.66 and as low as $1.42.

The top ETF exchange traded funds that EBS belongs to (by Net Assets): AVUV, VTI, XBI, IWM, FNDA.

EBS has outperformed the market in the last year with a price return of +31.3% while the SPY ETF gained +14.0%. EBS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +40.2% and +2.1%, respectively, while the SPY returned +4.0% and -0.2%, respectively.

EBS support price is $11.20 and resistance is $12.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EBS shares will trade within this expected range on the day.